REPROCELL
Litong LIU started working as a Research Assistant at Shizuoka University in October 2018 and held this position until June 2019. In August 2019, they began working as a Researcher at REPROCELL, and later in April 2023, they were promoted to the role of Chief Researcher.
Litong LIU earned a PhD in Bioscience from Shizuoka University from 2015 to 2018. Prior to that, they obtained a Master's degree in Applied Biochemistry from the same institution from 2013 to 2015.
REPROCELL
ReproCELL Incorporated is primarily engaged in the development of stem cell technologies. The Company operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES/ iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation. On February 10, 2014, it established a Kanagawa-based wholly owned subsidiary. On June 30, 2014, it acquired 85.2% interests in Reinnervate Limited, a UK-based company. On July 1, 2014, it fully acquired Reinnervate Limited. In July, 2014, it acquired BioServe Biotechnologies, Ltd. On September 2, 2014, it completed the acquisition of BioServe Biotechnologies, Ltd.